Previous close | 0.5250 |
Open | 0.5150 |
Bid | 0.5280 x N/A |
Ask | 0.5430 x N/A |
Day's range | 0.5150 - 0.5250 |
52-week range | 0.5150 - 0.5250 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced changes among the Non-Executive members of its Board of Directors. Professor Morten Asser Karsdal, MSc, PhD, mMBA and Ku
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease VIVIAD Phase 2b study did not meet its primary and key secondary endpointsVaroglutamstat was generally well tolerated with low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs in the clinical settingVIVIAD is a comprehensive, diligently designed and high-quality study; baseline demographics in the study were highly representative of early AD patient p